Imprimis Pharmaceuticals (IMMY) Receiving Somewhat Positive Media Coverage, Analysis Shows
News headlines about Imprimis Pharmaceuticals (NASDAQ:IMMY) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Imprimis Pharmaceuticals earned a news sentiment score of 0.24 on Accern’s scale. Accern also assigned headlines about the specialty pharmaceutical company an impact score of 46.9798776237253 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Separately, ValuEngine raised shares of Imprimis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.
Imprimis Pharmaceuticals (IMMY) traded up $0.02 during mid-day trading on Friday, reaching $1.74. 152,906 shares of the company’s stock were exchanged, compared to its average volume of 1,233,694. The company has a debt-to-equity ratio of 3.94, a quick ratio of 1.28 and a current ratio of 1.67. Imprimis Pharmaceuticals has a 1 year low of $1.35 and a 1 year high of $4.69. The company has a market capitalization of $35.63, a PE ratio of -1.89 and a beta of -0.27.
Imprimis Pharmaceuticals, Inc (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment.
Receive News & Ratings for Imprimis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imprimis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.